CytoSorbents Europe GmbH is based in Berlin, Germany, and is a wholly-owned subsidiary of CytoSorbents Corporation (NASDAQ: CTSO) in Monmouth Junction, New Jersey – USA, where the product CytoSorb is manufactured under ISO 13485 certification. CytoSorb is the flagship product of the company and protected by more than 32 issued US patents and multiple applications pending worldwide.
CytoSorbents Europe was founded in February 2012 by Dr. Christian Steiner and Dr. Phillip Chan, shortly after the product CytoSorb had received CE-mark approval. All sales and marketing activities as well as the majority of European scientific studies are managed and organized from Berlin.
CytoSorbents has experienced rapid growth following the successful launch of CytoSorb.
The product is marketed in 53 countries around the world including many countries in the E.U. such as Germany, the U.K., France, Italy and others, as well as in India, Turkey, the Middle East, Russia, and others. More than 800 clinical departments have adopted CytoSorb usage.
Moreover, the number of scientific publications and studies is continuously growing year after year. In addition to direct sales in Germany, all products are distributed abroad through specialist distributors and global partners such as Fresenius Medical Care (for a part of Europe) and Biocon Ltd. (India and surrounding emerging countries). All of these companies have many years of experience in intensive care medicine and have excellent knowledge of local markets.
CytoSorbents Corporation is listed on the NASDAQ since December 2014.